Amlodipine Besylate | Health Canada Patents | Expiry | Expiration | Dates | PharmaCompass.com

Please Wait

Applying Filters...

Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

Amlodipine Besylate
Health Canada Patents

EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

Contact Supplier

SPI Pharma has been solving formulation challenges using superior functional materials.

Contact Supplier

Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

Contact Supplier

Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

Contact Supplier

FAMAR CDMO- From early development to commercial manufacturing.

Contact Supplier

Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

Contact Supplier

Amlodipine Besylate

ACCESS ALL DATA, CHEMISTRY

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

111 API Suppliers, 41 USDMF, 44 CEP/COS, 25 JDMF, 25 EU WC, 91 KDMF, 27 NDC API, 56 Listed Suppliers, $ API Reference Price

111 API Suppliers
41 USDMF
44 CEP/COS
25 JDMF
25 EU WC
91 KDMF
27 NDC API
56 Listed Suppliers
$ API Reference Price

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

INTERMEDIATES

6 Intermediate Suppliers

6 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

773 FDF Dossiers, 429 FDA Orange Book, 47 Europe, 134 Canada, 28 South Africa, 135 Listed Dossiers

773 FDF Dossiers
429 FDA Orange Book
47 Europe
134 Canada
28 South Africa
135 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

TABLET;ORAL - EQ 10MG BASE, TABLET;ORAL - EQ 2.5MG BASE, TABLET;ORAL - EQ 5MG BASE, CAPSULE;ORAL - EQ 10MG BASE;20MG, CAPSULE;ORAL - EQ 10MG BASE;40MG, CAPSULE;ORAL - EQ 2.5MG BASE;10MG, CAPSULE;ORAL - EQ 5MG BASE;10MG, CAPSULE;ORAL - EQ 5MG BASE;20MG, CAPSULE;ORAL - EQ 5MG BASE;40MG, TABLET;ORAL - EQ 10MG BASE;14MG, TABLET;ORAL - EQ 2.5MG BASE;3.5MG, TABLET;ORAL - EQ 5MG BASE;7MG, TABLET;ORAL - EQ 10MG BASE;200MG, TABLET;ORAL - EQ 2.5MG BASE;200MG, TABLET;ORAL - EQ 5MG BASE;200MG, TABLET;ORAL - EQ 10MG BASE;EQ 10MG BASE, TABLET;ORAL - EQ 10MG BASE;EQ 20MG BASE, TABLET;ORAL - EQ 10MG BASE;EQ 40MG BASE, TABLET;ORAL - EQ 10MG BASE;EQ 80MG BASE, TABLET;ORAL - EQ 2.5MG BASE;EQ 10MG BASE, TABLET;ORAL - EQ 2.5MG BASE;EQ 20MG BASE, TABLET;ORAL - EQ 2.5MG BASE;EQ 40MG BASE, TABLET;ORAL - EQ 5MG BASE;EQ 10MG BASE, TABLET;ORAL - EQ 5MG BASE;EQ 20MG BASE, TABLET;ORAL - EQ 5MG BASE;EQ 40MG BASE, TABLET;ORAL - EQ 5MG BASE;EQ 80MG BASE, TABLET;ORAL - EQ 10MG BASE;160MG, TABLET;ORAL - EQ 10MG BASE;320MG, TABLET;ORAL - EQ 5MG BASE;160MG, TABLET;ORAL - EQ 5MG BASE;320MG, TABLET;ORAL - EQ 10MG BASE;20MG, TABLET;ORAL - EQ 10MG BASE;40MG, TABLET;ORAL - EQ 5MG BASE;20MG, TABLET;ORAL - EQ 5MG BASE;40MG, TABLET;ORAL - EQ 10MG BASE;12.5MG;160MG, TABLET;ORAL - EQ 10MG BASE;25MG;160MG, TABLET;ORAL - EQ 10MG BASE;25MG;320MG, TABLET;ORAL - EQ 5MG BASE;12.5MG;160MG, TABLET;ORAL - EQ 5MG BASE;25MG;160MG, TABLET;ORAL - EQ 10MG BASE;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 10MG BASE;80MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 5MG BASE;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 5MG BASE;80MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 10MG BASE
TABLET;ORAL - EQ 2.5MG BASE
TABLET;ORAL - EQ 5MG BASE
CAPSULE;ORAL - EQ 10MG BASE;20MG
CAPSULE;ORAL - EQ 10MG BASE;40MG
CAPSULE;ORAL - EQ 2.5MG BASE;10MG
CAPSULE;ORAL - EQ 5MG BASE;10MG
CAPSULE;ORAL - EQ 5MG BASE;20MG
CAPSULE;ORAL - EQ 5MG BASE;40MG
TABLET;ORAL - EQ 10MG BASE;14MG
TABLET;ORAL - EQ 2.5MG BASE;3.5MG
TABLET;ORAL - EQ 5MG BASE;7MG
TABLET;ORAL - EQ 10MG BASE;200MG
TABLET;ORAL - EQ 2.5MG BASE;200MG
TABLET;ORAL - EQ 5MG BASE;200MG
TABLET;ORAL - EQ 10MG BASE;EQ 10MG BASE
TABLET;ORAL - EQ 10MG BASE;EQ 20MG BASE
TABLET;ORAL - EQ 10MG BASE;EQ 40MG BASE
TABLET;ORAL - EQ 10MG BASE;EQ 80MG BASE
TABLET;ORAL - EQ 2.5MG BASE;EQ 10MG BASE
TABLET;ORAL - EQ 2.5MG BASE;EQ 20MG BASE
TABLET;ORAL - EQ 2.5MG BASE;EQ 40MG BASE
TABLET;ORAL - EQ 5MG BASE;EQ 10MG BASE
TABLET;ORAL - EQ 5MG BASE;EQ 20MG BASE
TABLET;ORAL - EQ 5MG BASE;EQ 40MG BASE
TABLET;ORAL - EQ 5MG BASE;EQ 80MG BASE
TABLET;ORAL - EQ 10MG BASE;160MG
TABLET;ORAL - EQ 10MG BASE;320MG
TABLET;ORAL - EQ 5MG BASE;160MG
TABLET;ORAL - EQ 5MG BASE;320MG
TABLET;ORAL - EQ 10MG BASE;20MG
TABLET;ORAL - EQ 10MG BASE;40MG
TABLET;ORAL - EQ 5MG BASE;20MG
TABLET;ORAL - EQ 5MG BASE;40MG
TABLET;ORAL - EQ 10MG BASE;12.5MG;160MG
TABLET;ORAL - EQ 10MG BASE;25MG;160MG
TABLET;ORAL - EQ 10MG BASE;25MG;320MG
TABLET;ORAL - EQ 5MG BASE;12.5MG;160MG
TABLET;ORAL - EQ 5MG BASE;25MG;160MG
TABLET;ORAL - EQ 10MG BASE;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 10MG BASE;80MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 5MG BASE;40MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
TABLET;ORAL - EQ 5MG BASE;80MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

RELATED EXCIPIENT COMPANIES

1 Minakem, 3 Rochem International Inc, 22 SPI Pharma, 2 Seqens, 19 DKSH, 1 Pharm-RX Chemical, 8 Faran Shimi Pharmaceutical, 8 Boai NKY Pharmaceuticals Ltd, 1 Chynops Pharma, 7 Gangwal Healthcare, 11 Nanjing Well Pharmaceutical, 2 Pfanstiehl, 1 Pramukh Pharmachem, 4 ACG Worldwide, 5 Actylis, 2 Aeon Procare, 3 Alcedo Pharmachem, 11 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 1 Avesta Pharma, 35 BASF, 3 Clariant, 11 Corel Pharma Chem, 7 DFE Pharma, 2 Finar, 13 Gangwal Chemicals, 7 Ideal Cures Pvt Ltd, 5 Ingredion Pharma Solutions, 39 Kerry, 4 Kima Chemical, 6 Lonza Capsugel, 20 Microlex e.U, 1 Nanjing Bold Chemical, 1 NEWEDGE Overseas, 2 Nomisma Healthcare, 4 Novo Excipients, 5 Pharmatrans-Sanaq, 8 Pluviaendo, 5 Prachin Chemical, 1 Qianhao Chemical (Hebei) Co., Ltd, 2 Qualicaps, 23 Roquette, 16 Seppic, 7 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Shijiazhuang Huaxu Pharmaceutical, 12 Sigachi Industries, 3 The Dow Chemical Company, 2 Ulanqab Kema New Material, 1 Valens Pharmachem, 4 Vasa Pharmachem, 1 Vertellus

EXCIPIENTS BY APPLICATIONS

107 Fillers, Diluents & Binders, 60 Coating Systems & Additives, 49 Disintegrants & Superdisintegrants, 44 Direct Compression, 42 Thickeners and Stabilizers, 38 Solubilizers, 34 Controlled & Modified Release, 32 Lubricants & Glidants, 32 Granulation, 27 Topical, 24 Parenteral, 24 Film Formers & Plasticizers, 22 Chewable & Orodispersible Aids, 20 Taste Masking, 18 Co-Processed Excipients, 13 Emulsifying Agents, 10 Rheology Modifiers, 9 Empty Capsules, 9 API Stability Enhancers, 8 Surfactant & Foaming Agents, 5 Coloring Agents, 4 Vegetarian Capsules

107 Fillers, Diluents & Binders
60 Coating Systems & Additives
49 Disintegrants & Superdisintegrants
44 Direct Compression
42 Thickeners and Stabilizers
38 Solubilizers
34 Controlled & Modified Release
32 Lubricants & Glidants
32 Granulation
27 Topical
24 Parenteral
24 Film Formers & Plasticizers
22 Chewable & Orodispersible Aids
20 Taste Masking
18 Co-Processed Excipients
13 Emulsifying Agents
10 Rheology Modifiers
9 Empty Capsules
9 API Stability Enhancers
8 Surfactant & Foaming Agents
5 Coloring Agents
4 Vegetarian Capsules

DIGITAL CONTENT

41 NEWS #PharmaBuzz

41 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

6 US Medicaid Prescriptions, 40 Finished Drug Prices, 1 Annual Reports

6 US Medicaid Prescriptions
40 Finished Drug Prices
1 Annual Reports

MARKET PLACE

36 APIs, 7 FDF Dossiers

36 APIs
7 FDF Dossiers

PATENTS & EXCLUSIVITIES

33 US Patents, 6 Health Canada Patents

33 US Patents
6 Health Canada Patents

REF. STANDARDS & IMPURITIES

5 EDQM, 1 USP, 7 JP, 1 Others

5 EDQM
1 USP
7 JP
1 Others

$ API Ref.Price (USD/KG) : 116 Xls

Filters

Reset all filters

Filters

FILTER :

filter Company Reset all filters

6 All

01 3Pfizer Canada Inc.

02 3Blank

filter Patent Reset all filters

6 All

01 31253865

02 32170278

filter Product Reset all filters

6 All

01 3Amlodipine Besylate

02 3Blank

filter Dosage Reset all filters

6 All

01 3Tablet

02 3Blank

filter Exp Date Reset all filters

6 All

01 32006-05-09

02 32014-08-10

Product Main Page

01

Pfizer Canada Inc.

Amlodipine Besylate

Biotech Digital Meet

Not Confirmed

Pfizer Canada Inc.

Biotech Digital Meet

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2014-08-10

Date Granted : 1999-08-03

Amlodipine Besylate

Brand Name : NORVASC

Patent Number : 2170278

Filing Date : 1994-08-10

Strength per Unit : 2.5 mg / tablet

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2014-08-10

Date Granted : 1999-08-03

Portfolio PDF

Product Web Link

Digital Content

02

Pfizer Canada Inc.

Amlodipine Besylate

Biotech Digital Meet

Not Confirmed

Pfizer Canada Inc.

Biotech Digital Meet

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2014-08-10

Date Granted : 1999-08-03

Amlodipine Besylate

Brand Name : NORVASC

Patent Number : 2170278

Filing Date : 1994-08-10

Strength per Unit : 5 mg / tablet

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2014-08-10

Date Granted : 1999-08-03

Portfolio PDF

Product Web Link

Digital Content

03

Pfizer Canada Inc.

Amlodipine Besylate

Biotech Digital Meet

Not Confirmed

Pfizer Canada Inc.

Biotech Digital Meet

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2014-08-10

Date Granted : 1999-08-03

Amlodipine Besylate

Brand Name : NORVASC

Patent Number : 2170278

Filing Date : 1994-08-10

Strength per Unit : 10 mg / tablets

Dosage Form : Tablet

Human Or VET : Human

Route of Administration : Oral

Patent Expiration Date : 2014-08-10

Date Granted : 1999-08-03

Portfolio PDF

Product Web Link

Digital Content

04

Amlodipine Besylate

Biotech Digital Meet

Not Confirmed

Country

Biotech Digital Meet

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2006-05-09

Date Granted :

Amlodipine Besylate

Brand Name :

Patent Number : 1253865

Filing Date :

Strength per Unit :

Dosage Form :

Human Or VET :

Route of Administration :

Patent Expiration Date : 2006-05-09

Date Granted :

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

05

Amlodipine Besylate

Biotech Digital Meet

Not Confirmed

Country

Biotech Digital Meet

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2006-05-09

Date Granted :

Amlodipine Besylate

Brand Name :

Patent Number : 1253865

Filing Date :

Strength per Unit :

Dosage Form :

Human Or VET :

Route of Administration :

Patent Expiration Date : 2006-05-09

Date Granted :

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

06

Amlodipine Besylate

Biotech Digital Meet

Not Confirmed

Country

Biotech Digital Meet

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Patent Expiration Date : 2006-05-09

Date Granted :

Amlodipine Besylate

Brand Name :

Patent Number : 1253865

Filing Date :

Strength per Unit :

Dosage Form :

Human Or VET :

Route of Administration :

Patent Expiration Date : 2006-05-09

Date Granted :

Portfolio PDF

Product Web Link

Virtual Booth

Digital Content

Website

Corporate PDF

Contact us
to update this info

Privacy policy
Terms and conditions
Disclaimers
ASK US!